Loading
A phase 1/2 trial of Alcestobart run by Nanjing Leads Biolabs Co.,Ltd, completed.
A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors is a phase 1/2 interventional study registered as NCT05516914 by Nanjing Leads Biolabs Co.,Ltd, with 98 participants enrolled, started 2022-09-01. Conditions recorded: Malignant Tumors. Interventions recorded: LBL-007 Injection, Tislelizumab Injection, Cisplatin Injection, Gemcitabine Hydrochloride for Injection and Docetaxel injection.
Shares Alcestobart, Nanjing Leads Biolabs, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Alcestobart, Nanjing Leads Biolabs, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Alcestobart, Nanjing Leads Biolabs and the tag pipeline.
Shares Alcestobart, Nanjing Leads Biolabs and the tag pipeline.
Shares Alcestobart, Nanjing Leads Biolabs and the tag pipeline.
Shares Alcestobart, Nanjing Leads Biolabs and the tag pipeline.
Shares Nanjing Leads Biolabs, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Nanjing Leads Biolabs, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/